DMAC - DiaMedica Therapeutics Inc.
| Previous Close | 2.8200 |
| Open | 2.8000 |
| Bid | 2.7100 x 800 |
| Ask | 2.9000 x 1300 |
| Day's Range | 2.7514 - 2.8011 |
| 52 Week Range | 1.7000 - 5.9300 |
| Volume | 11,401 |
| Avg. Volume | 38,531 |
| Market Cap | 35M |
| Beta (3Y Monthly) | 2.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9070 |
| Earnings Date | Nov 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
DiaMedica Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update
MINNEAPOLIS-- -- Phase II Study of DM199 in Chronic Kidney Disease Commences Screening REMEDY Phase II Study of DM199 in Acute Ischemic Stroke Completes Enrollment Management Team Strengthens with Sydney Gilman, Ph.D., Vice President of Regulatory Affairs Conference Call with Management Tomorrow, November 14 at 7am CT DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused ...
- Business Wire
DiaMedica Therapeutics to Report Third Quarter 2019 Financials and Provide a Business Update November 14, 2019
DiaMedica Therapeutics Inc. today announced that its third quarter 2019 financial results will be released after the markets close on Wednesday, November 13th. DiaMedica will host a live conference call on Thursday, November 14th at 7:00 AM Central Time to discuss its business update and financial results.
- Business Wire
DiaMedica Therapeutics to Participate in 10th Annual Craig-Hallum Alpha Select Conference
DiaMedica Therapeutics Inc. today announced that Rick Pauls, President & Chief Executive Officer, will meet with institutional investors at the 10th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 12, 2019, at the Sheraton New York Times Square Hotel in New York City.
- Business Wire
DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease
DiaMedica Therapeutics Inc. (DMAC) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Phase II clinical trial protocol for the treatment of Chronic Kidney Disease (CKD). The Phase II trial is designed to assess the safety and efficacy of DM199 in the treatment of CKD in two cohorts: patients with CKD caused by IgA nephropathy (IgAN) and hypertensive African American patients with CKD.
- GlobeNewswire
DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019
MINNEAPOLIS, Sept. 06, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will attend the Lake Street Capital Markets 3rd Annual Best Ideas.
- GlobeNewswire
DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference
MINNEAPOLIS, Sept. 03, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor.
- GlobeNewswire
DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update
Phase Ib study of DM199 in Chronic Kidney Disease enrollment completeEncouraging early signals in mechanism biomarkers (NO and PGE2), Kidney function (eGFR) and urine albumin.
- GlobeNewswire
DiaMedica Therapeutics to Present at the 2019 Intellisight Investor Conference on August 14, 2019
MINNEAPOLIS, Aug. 12, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that Rick Pauls, President and CEO, will be presenting at the 2019 Intellisight.
- GlobeNewswire
DiaMedica Therapeutics to Report Second Quarter 2019 Financials and Provide a Business Update August 13, 2019
MINNEAPOLIS, Aug. 08, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2019 financial results will be released after the markets close.
- Benzinga
The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 20) Abbott Laboratories (NYSE: ABT ) ANI Pharmaceuticals ...
- Benzinga
The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 19) Abbott Laboratories (NYSE: ABT ) CareDx Inc (NASDAQ: ...
- GlobeNewswire
DiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants
The study also demonstrated a dose range which the Company believes will restore normal KLK1 levels in CKD patients. It is noteworthy that the pharmacokinetic (PK) profile in CKD subjects after dosing was similar to the PK profile in healthy volunteers.
- GlobeNewswire
DiaMedica Therapeutics Announces Formation of Scientific Advisory Board for Kidney Disease
DiaMedica Therapeutics Inc. (DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today announced the formation of a Scientific Advisory Board (“SAB”) for chronic kidney disease (“CKD”). The members of the SAB are world-leading experts in CKD and hypertension. The SAB will work closely with DiaMedica’s senior management team to advance the company’s lead product candidate, DM199, in the treatment of chronic kidney disease.
- ACCESSWIRE
DiaMedica Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 14, 2019 / DiaMedica Therapeutics, Inc. (NASDAQ: DMAC ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 14, 2019 at 8:00 ...
- GlobeNewswire
DiaMedica Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Update
Phase Ib study of DM199 in Chronic Kidney Disease nearing full enrollmentCompletion of new cGMP manufacturing run of DM199Conference call with management tomorrow, May 14, 2019.
- GlobeNewswire
DiaMedica Therapeutics to Report First Quarter 2019 Financials and Provide an Update on Development Programs on May 14, 2019
MINNEAPOLIS, May 06, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its first quarter 2019 financial results will be released after market close on.
- GlobeNewswire
DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting
DiaMedica Therapeutics Inc. (DMAC), a clinical-stage biotechnology company, today announced that Dr Harry Alcorn, its Chief Medical Officer will be presenting “CKD New Therapeutic Development: DM199 for Chronic Kidney Disease” at the Chronic Kidney Disease Drug Development (“CKD3”) summit in Boston on Tuesday May 7, 2019, at 1:30 Eastern Time. CKD3 is a uniquely focused conference that unites key opinion leaders to identify and discuss critical factors in determining the success of current chronic kidney disease (“CKD”) pipelines and evaluate new treatments that have the potential to significantly impact the standard of care for this serious unmet medical need. Leading experts from innovative biotechnology and pharmaceutical companies, academia and key service providers come together at the CKD3 summit to present comprehensive insight into the cutting-edge progress of CKD drug development research.
- GlobeNewswire
DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update
Dosed first patients in Phase Ib study of DM199 in Chronic Kidney Disease patients under an IND accepted by the FDA in 2018; Plan to initiate Phase II studies in 2H 2019Acute.
- GlobeNewswire
DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
MINNEAPOLIS, March 18, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March.
- GlobeNewswire
DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019
MINNEAPOLIS, March 12, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The.
- GlobeNewswire
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
DiaMedica Therapeutics Inc. (DMAC), a clinical-stage biotechnology company, today announced that it has initiated dosing patients with chronic kidney disease (“CKD”) in a Phase Ib clinical study evaluating DM199. The Phase 1b study, conducted in the US, is a multi-center, open label clinical trial to evaluate the safety, tolerability and pharmacokinetics of three dose levels of DM199 in 32 patients with moderate and severe CKD. “This study will assist in determining dose levels required to restore normal KLK1 protein levels in patients with CKD and provide additional insights about the specific CKD patient populations that may benefit most from DM199 treatment and to guide the design of upcoming Phase II studies,” said Dr. Harry Alcorn, Chief Medical Officer at DiaMedica Therapeutics.
- GlobeNewswire
DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
MINNEAPOLIS, Jan. 22, 2019 -- DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announces the publication of a paper titled “Human Tissue Kallikrein In The Treatment Of Acute Ischemic.
- PR Newswire
OTC Markets Group Announces Quarterly Index Performance and Rebalancing
NEW YORK , Jan. 16, 2018 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the fourth quarter 2018 performance ...
- Benzinga
The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks The following biotech stocks struck 52-week highs Jan. 9: China SXT Pharmaceuticals Inc (NASDAQ: SXTC ...